NAC add on to the treatment of refractory obssessive compulsive disorder: A double-blind clinical trial

NAC add on to the treatment of refractory obssessive compulsive disorder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138806101743N2

Enrollment

Registered

2009-10-12

Start date

2009-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-compulsive disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: NAC, 2400 mg, daily, for 12 weeks. Intervention 2: Placebo, 2400 mg, daily, for 12 weeks.

Treatment - Drugs

NAC, 2400 mg, daily, for 12 weeks

Placebo, 2400 mg, daily, for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Suffering from OCD, taking a therapeutic dose of a SSRI or Clomipramine, at least for 12 weeks, Y_BOSC score of 16 or greater Exclusion criteria: primary diagnosis of psychosis or bipolar mood disorder, substance abuse or dependency, uncontrolled medical condition, having had a pervious trial of Memantine, pregnancy or breast feeding, rising liver enzymes to more than twice of normal range during intervention, presence of epilepsy, presence of suicidal thinking, presence of MDD

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of symptoms of OCD. Timepoint: Basline and every 4 weeks. Method of measurement: Y_BOCS and CGI Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamid Mohammadbigi

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026